ClinicalTrials.gov
ClinicalTrials.gov Menu

Tumor Metabolism of Lung Cancer in Patients Who Underwent Percutaneous Radiation Measured With F-18-FDG-PET

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00180154
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : August 24, 2011
Sponsor:
Information provided by (Responsible Party):
Jörg Kotzerke, Technische Universität Dresden

Brief Summary:
The purpose of the study is to describe the regional and global FDG-kinetics in non-small-cell lung cancer (NSCLC) during percutaneous radiation therapy.

Condition or disease
Lung Cancer

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Tumor Metabolism of Lung Cancer Underwent Percutaneous Radiation Measured With F-18-FDG-PET
Study Start Date : July 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study includes consecutive patients from Department of Radiooncology with inoperable non-small cell lung cancer (NSCLC) intended for a curative radiotherapy.
Criteria

Inclusion Criteria:

  • Histologically confirmed NSCLC not curable by surgery
  • Karnofsky > 80%
  • Tumor volume and localization allow curative radiotherapy
  • Written consent

Exclusion Criteria:

  • Metastases
  • Diabetes
  • Pregnancy
  • Psychiatric impairment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00180154


Locations
Germany
Department of Nuclear Medicine
Dresden, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Investigators
Principal Investigator: Joerg Kotzerke, MD Department of Nuclear Medicine

Responsible Party: Jörg Kotzerke, Prof. Dr., Technische Universität Dresden
ClinicalTrials.gov Identifier: NCT00180154     History of Changes
Other Study ID Numbers: BCA-FDG-FU
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: August 24, 2011
Last Verified: August 2011

Keywords provided by Jörg Kotzerke, Technische Universität Dresden:
radiation therapy
F-18-FDG
NSCLC

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Fluorodeoxyglucose F18
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action